中文

复星医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥10.07B+6.9%
Gross profit¥5.01B
Operating income¥1.38B
Net income¥1.08B+14.7%
Gross margin49.7%Net margin 10.7%
Revenue Q/Q-17.9%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥5.07B50.3%
R&D¥0.90B8.9%
SG&A¥3.27B32.5%
Tax & other¥0.30B2.9%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

南山铝业海航控股圆通速递恒瑞医药万华化学恒力石化江西铜业中航机载国电南瑞小商品城华鲁恒升片仔癀

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies